AUDUSD: Weakens, Sees Corrective Pullback Risk
Mar 14, 2016
Jeremy Parkinson
Finance
AUDUSD. Having the pair capped its strength at 0.7593 level to close lower on Monday, a move further lower is now underway. On the downside, support resides at the 0.7450 level where a breach will aim at the 0.7400 level. Below that level will set the stage for a run at the 0.7350 level with […]
Coffee Downtrend Set To End
Mar 14, 2016
Jeremy Parkinson
Finance
The coffee price has risen from its lows and this could well be the start of the expected big rally which has been laid out previously. Let’s review the daily chart and monthly charts. COFFEE DAILY CHART We can see price has been moving up nicely since the January 2016 low at $112.53. To really […]
Jamba Inc. Misses Earnings Estimates, Beats On Revenue
Mar 14, 2016
Jeremy Parkinson
Finance
Jamba Inc. (JMBA – Snapshot Report) just released their fourth quarter fiscal 2015 earnings results, posting an earnings loss of $-0.28 per share and revenue of $19.5 million. Currently, JMBA has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this […]
Fed Market Intervention And Stock Market Fraud
Mar 14, 2016
Jeremy Parkinson
Finance
The Shadow of Truth presents a “Market Update” in which we discuss the extreme fraud and deception that has engulfed the stock market – see below for our audio discussion: The governments in my view, with their agents the Federal Reserve and other central banks and with the treasury department, they will do anything not […]
ETF Stats For February 2016: Count Up, Assets Down
Mar 14, 2016
Jeremy Parkinson
Finance
Thirteen new products came to market in February: seven exchange-traded funds (“ETFs”) and six exchange-traded notes (“ETNs”). Closures were on the light side, with just three products being liquidated during the month. The net increase of 10 listings pushes the overall count to 1,863, consisting of 1,659 ETFs and 204 ETNs. Assets declined for the […]
Waiting On The Fed
Mar 14, 2016
Jeremy Parkinson
Finance
“There are two types of people who will tell you that you cannot make a difference in this world: those who are afraid to try and those who are afraid you will succeed.” –Ray Goforth Pretty quiet markets today but a few stocks are moving well such as AMZN and a new position of ours, […]
A $1.58 Million Portfolio With No Captain
Mar 14, 2016
Jeremy Parkinson
Finance
Has your financial advisor contacted you lately? Although global stock markets (see:VT) have recovered from their earlier in the year losses, they could’ve revealed flaws with your investment portfolio’s design. Often, flaws that are camouflaged by rising markets are exposed and exploited in rocky markets. Ultimately, advisors should take responsibility for the investment recommendations they make and the advice given […]
Does Oracle Have What It Takes To Compete With Amazon?
Mar 14, 2016
Jeremy Parkinson
Finance
Photo Credit: May Wong Oracle Corporation (ORCL) Information Technology – Software | Reports March 15, After Market Closes As we close the door on fourth quarter earnings another opens when Oracle (ORCL) reports its FQ3 earnings tomorrow after the market closes, the first report of the Q1 2016 season. Oracle is coming off a better than expected […]
Senseonics IPO: We Are Cautious At This Early Stage
Mar 14, 2016
Jeremy Parkinson
Finance
Senseonics Holdings (Pending:SENS) expects to raise at least $55.5 million in its upcoming IPO. Based in Germantown, Maryland, Senseonics Holdings is a medical technology company that designs, develops and commercializes glucose monitoring systems for use by people with diabetes. We previewed SENS on our IPO Insights platform earlier last week. SENS currently trades on the OTCBB under symbol SENH. […]
Chart Of The Week – Biotechs Are Oversold
Mar 14, 2016
Jeremy Parkinson
Finance
Biotech stocks have taken a beating the last few months, down roughly 35% since peaking in July of last year. And for good reason I think. Biotech at the top was sporting a pretty rich multiple, 25 times forward earnings for the biotech stocks in the S&P 500 and a lot more than that for […]